

Special Issue

Exploiting Metabolic Weaknesses: A Novel Approach to Overcome Drug Resistance in Cancer Therapy

Message from the Guest Editor

Immune cells face a metabolic disadvantage due to a lack of carbon nutrients, which results from competition with tumor cells in the tumor microenvironment (TME).

By understanding how cellular metabolism influences cancer cells, we aim to identify strategies to circumvent resistance and improve cancer treatment. This Special Issue of the Journal of Personalized Medicine aims to highlight the latest studies in the field of tumor metabolism as well as tumor immunometabolism.

Topics of interest include novel insights into metabolomics, metabolites, metabolic pathways/immune functions, inflammation/metabolism, and therapeutic implications.

Guest Editor

Dr. Medhi Wangpaichitr

1. Department of Veterans Affairs, Miami VA Healthcare System, Research Service, Miami, FL, USA
2. Department of Surgery, Cardiothoracic Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA

Deadline for manuscript submissions

closed (15 October 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/206071

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).